Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 May 26;31(17):2080–2086. doi: 10.1093/eurheartj/ehq152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.

PMC Copyright notice

Time-course of 25 published randomized controlled studies (identified by acronyms, if any, or drug and year of publication) in pulmonary arterial hypertension as of May 2010. Colour code identifies the design of the study: monotherapy (black): investigational drug vs. placebo in patients naive for pulmonary arterial hypertension approved drugs. Monotherapy and/or sequential combination (red): investigational drug vs. placebo in patients either naive for, or treated with pulmonary arterial hypertension approved drugs. Upfront combination (light blue): single drug vs. combination of two drugs in patients naive for pulmonary arterial hypertension approved drugs.